KalVista promotes CFO/CBO Palleiko to President; cites $190M cash for sebetralstat launch prep

KalVista Pharmaceuticals, Inc.

Benjamin L. Palleiko appointed President effective Jan 4, 2023, while retaining CFO and CBO roles.
Promotion follows $58M registered direct offering in Dec 2022 at 17% premium; pro forma cash ~$190M.
Palleiko to lead commercial organization for planned launch of sebetralstat, an oral HAE therapy in Phase 3.
KalVista expects KONFIDENT Phase 3 data in H2 2023 and NDA filing in H1 2024; cash runway into 2025.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Benjamin L. Palleiko

President

KALV · KalVista Pharmaceuticals, Inc.

Effective: 2023-01-04
Filed: January 5, 2023, 6:59 PM ET

On January 4, 2023, KalVista Pharmaceuticals, Inc. (the “Company”) announced the appointment of Benjamin L. Palleiko, currently the Company’s Chief Business Officer and Chief Financial Officer, to the position of President of the Company, effective as of January 4, 2023.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Benjamin L. Palleiko was appointed as President at KalVista Pharmaceuticals, Inc..

Action: appointed
Role: President

Exact text from the filing

On January 4, 2023, KalVista Pharmaceuticals, Inc. (the “Company”) announced the appointment of Benjamin L. Palleiko, currently the Company’s Chief Business Officer and Chief Financial Officer, to the position of President of the Company, effective as of January 4, 2023.

View on SEC.gov

KalVista Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-000230

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.